Toward a flexible facial analysis framework in OpenISS for visual effects

Facial analysis, including tasks such as face detection, facial landmark detection, and facial expression recognition, is a significant research domain in computer vision for visual effects. It can be used in various domains such as facial feature mapping for movie animation, biometrics/face recognition for security systems, and driver fatigue monitoring for transportation safety assistance. Most applications involve basic face and landmark detection as preliminary analysis approaches before proceeding into further specialized processing applications. As technology develops, there are plenty of implementations and resources for each task available for researchers, but the key missing properties among them all are fexibility and usability. The integration of functionality components involves complex configurations for each connection joint which is typically problematic with poor reusability and adjustability. The lack of support for integrating different functionality components greatly impact the research effort and cost for individual researchers, which also leads us to the idea of providing a framework solution that can help regarding the issue once and for all. To address this problem, we propose a user-friendly and highly expandable facial analysis framework solution. It contains a core that supports fundamental services for the framework, and a facial analysis module composed of implementations for facial analysis tasks. We evaluate our framework solution and achieve our goals of instantiating the facial analysis specialized framework, which essentially perform tasks in face detection, facial landmark detection, and facial expression recognition. This framework solution as a whole, solves the industry problem of lacking an execution platform for integrated facial analysis implementations and fills the gap in visual effects industry

Social work with airports passengers

Social work at the airport is in to offer to passengers social services. The main methodological position is that people are under stress, which characterized by a particular set of characteristics in appearance and behavior. In such circumstances passenger attracts in his actions some attention. Only person whom he trusts can help him with the documents or psychologically

Evaluation of PD-L1 expression in various formalin-fixed paraffin embedded tumour tissue samples using SP263, SP142 and QR1 antibody clones

Background & objectives: Cancer cells can avoid immune destruction through the inhibitory ligand PD-L1. PD-1 is a surface cell receptor, part of the immunoglobulin family. Its ligand PD-L1 is expressed by tumour cells and stromal tumour infltrating lymphocytes (TIL). Methods: Forty-four cancer cases were included in this study (24 triple-negative breast cancers (TNBC), 10 non-small cell lung cancer (NSCLC) and 10 malignant melanoma cases). Three clones of monoclonal primary antibodies were compared: QR1 (Quartett), SP 142 and SP263 (Ventana). For visualization, ultraView Universal DAB Detection Kit from Ventana was used on an automated platform for immunohistochemical staining Ventana BenchMark GX. Results: Comparing the sensitivity of two different clones on same tissue samples from TNBC, we found that the QR1 clone gave higher percentage of positive cells than clone SP142, but there was no statistically significant difference. Comparing the sensitivity of two different clones on same tissue samples from malignant melanoma, the SP263 clone gave higher percentage of positive cells than the QR1 clone, but again the difference was not statistically significant. Comparing the sensitivity of two different clones on same tissue samples from NSCLC, we found higher percentage of positive cells using the QR1 clone in comparison with the SP142 clone, but once again, the difference was not statistically significant. Conclusion: The three different antibody clones from two manufacturers Ventana and Quartett, gave comparable results with no statistically significant difference in staining intensity/ percentage of positive tumour and/or immune cells. Therefore, different PD-L1 clones from different manufacturers can potentially be used to evaluate the PD- L1 status in different tumour tissues. Due to the serious implications of the PD-L1 analysis in further treatment decisions for cancer patients, every antibody clone, staining protocol and evaluation process should be carefully and meticulously validated